Non-valvular atrial fibrillation: impact of apixaban on patient outcomes

References

• LipGYHBrechinCMLaneDAThe global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and EuropeChest201214261489149822459778
   PubMed Web of Science ®Google Scholar
• ChughSSHavmoellerRNarayananKWorldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 StudyCirculation2014129883784724345399
   PubMed Web of Science ®Google Scholar
• LipGYTseHFLaneDAAtrial fibrillationLancet2012379981664866122166900
   PubMed Web of Science ®Google Scholar
• MorganCLMcEwanPTukiendorfARobinsonPAClemensAPlumbJMWarfarin treatment in patients with AF: observing outcomes associated with varying levels of INR controlThromb Res20091241374119062079
   PubMed Web of Science ®Google Scholar
• ReynoldsMWFahrbachKHauchOWarfarin anticoagulation and outcomes in patients with AF: a systematic review and metaanalysisChest200412661938194515596696
   PubMed Web of Science ®Google Scholar
• RaghavanNFrostCEYuZApixaban metabolism and pharmacokinetics after oral administration to humansDrug Metab Dispos2009371748118832478
   PubMed Web of Science ®Google Scholar
• HartRGPearceLAAguilarMIMeta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular AFAnn Intern Med20071461285786717577005
   PubMed Web of Science ®Google Scholar
• ConnollySJEikelboomJJoynerCAVERROES Steering Committee and InvestigatorsApixaban in patients with atrial fibrillationN Engl J Med2011364980681721309657
   PubMed Web of Science ®Google Scholar
• GrangerCBAlexanderJHMcMurrayJJARISTOTLE InvestigatorsApixaban versus warfarin in patients with AFN Engl J Med20113651198199221870978
   PubMed Web of Science ®Google Scholar
• EastonJDLopesRDBahitMCARISTOTLE Committees and InvestigatorsApixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trialLancet Neurol201211650351122572202
   PubMed Web of Science ®Google Scholar
• McMurrayJJEzekowitzJALewisBSARISTOTLE Committees and InvestigatorsLeft ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trialCirc Heart Fail20136345146023575255
   PubMed Web of Science ®Google Scholar
• BahitMCLopesRDWojdylaDMApixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trialInt J Cardiol2013170221522024192334
   PubMed Web of Science ®Google Scholar
• HuPTLopesRDStevensSREfficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation and peripheral artery disease: insights from the ARISTOTLE trialJ Am Heart Assoc201761e00469928096100
   PubMed Web of Science ®Google Scholar
• HohnloserSHHijaziZThomasLEfficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trialEur Heart J201233222821283022933567
   PubMed Web of Science ®Google Scholar
• EzekowitzJALewisBSLopesRDClinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trialEur Heart J Cardiovasc Pharmacother201512869427533976
   PubMed Web of Science ®Google Scholar
• Jaspers FocksJBrouwerMAWojdylaDMPolypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trialBMJ2016353i286827306620
   PubMed Web of Science ®Google Scholar
• RaoMPHalvorsenSWojdylaDARISTOTLE Committee and InvestigatorsBlood pressure control and risk of stroke or systemic embolism in patients with atrial fibrillation: results from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trialJ Am Heart Assoc2015412e00201526627878
   PubMed Web of Science ®Google Scholar
• GarciaDAWallentinLLopesRDApixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation trialAm Heart J2013166354955824016506
   PubMed Web of Science ®Google Scholar
• ColemanCIPeacockWFBunzTJAlbertsMJEffectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in patients with nonvalvular AF and previous stroke or transient ischemic attackStroke20174882142214928655814
   PubMed Web of Science ®Google Scholar
• DeitelzweigSFarmerCLuoXRisk of major bleeding in patients with non-valvular AF treated with oral anticoagulants: a systematic review of real-world observational studiesCurr Med Res Opin201723915831594
   Web of Science ®Google Scholar
• LipGYKeshishianAKambleSReal-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysisThromb Haemost2016116597598627538358
   PubMed Web of Science ®Google Scholar
• XuWWHuSJWuTRisk analysis of new oral anticoagulants for gastrointestinal bleeding and intracranial hemorrhage in AF patients: a systematic review and network meta-analysisJ Zhejiang Univ Sci B201718756757628681581
   PubMed Web of Science ®Google Scholar
• YaoXAbrahamNSSangaralinghamLREffectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular AFJ Am Heart Assoc20165e00372527412905
   PubMed Web of Science ®Google Scholar
• AminAKeshishianATrocioJRisk of stroke/systemic embolism, major bleeding and associated costs in non-valvular AF patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States Medicare populationCurr Med Res Opin20173391595160428635338
   PubMed Web of Science ®Google Scholar
• TawfikABieleckiJMKrahnMSystematic review and network meta-analysis of stroke prevention treatments in patients with AFClin Pharmacol201689310727570467
   PubMedGoogle Scholar
• LipGYHSkjøthFNielsenPBKjældgaardJNLarsenTBEffectiveness and safety of standard-dose nonvitamin K antagonist oral antico-agulants and warfarin among patients with AF with a single stroke risk factor: A Nationwide Cohort StudyJAMA Cardiol20172887288128614582
   PubMed Web of Science ®Google Scholar
• ColemanCIPeacockWFAntzMComparative effectiveness and safety of apixaban and vitamin K antagonist therapy in patients with nonvalvular atrial fibrillation treated in routine German practiceHeart Lung Circ Epub201753
   Web of Science ®Google Scholar
• LarsenTBSkjøthFNielsenPBKjældgaardJNLipGYComparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with AF: propensity weighted nationwide cohort studyBMJ2016353i318927312796
   PubMed Web of Science ®Google Scholar
• NielsenPBSkjøthFSøgaardMKjældgaardJNLipGYLarsenTBEffectiveness and safety of reduced-dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with AF: propensity weighted nationwide cohort studyBMJ2017356j51028188243
   PubMed Web of Science ®Google Scholar
• HalvorsenSAtarDYangHEfficacy and safety of apixaban compared with warfarin according to age for stroke prevention in AF: observations from the ARISTOTLE trialEur Heart J201435281864187224561548
   PubMed Web of Science ®Google Scholar
• BarraMEFanikosJConnorsJMSylvesterKWPiazzaGGoldhaberSZEvaluation of dose-reduced direct oral anticoagulant therapyAm J Med2016129111198120427341955
   PubMed Web of Science ®Google Scholar
• YaoXShahNDSangaralinghamLRGershBJNoseworthyPANon-Vitamin K antagonist oral anticoagulant dosing in patients with AF and renal dysfunctionJ Am Coll Cardiol201769232779279028595692
   PubMed Web of Science ®Google Scholar
• AlexanderJHAnderssonULopesRDARISTOTLE InvestigatorsApixaban 5 mg twice daily and clinical outcomes in patients with AF and advanced age, low body weight, or high creatinine: a secondary analysis of a randomized clinical trialJAMA Cardiol2016166738127463942
   PubMed Web of Science ®Google Scholar
• LinJTrocioJGuptaKMajor bleeding risk and healthcare economic outcomes of non-valvular AF patients newly-initiated with oral anticoagulant therapy in the real-world settingJ Med Econ201720995296128604139
   PubMed Web of Science ®Google Scholar
• AthanasakisKBoubouchairopoulouNKarampliECost effectiveness of apixaban versus warfarin or aspirin for stroke prevention in patients with AF: a Greek perspectiveAm J Cardiovasc Drugs201717212313327882517
   PubMed Web of Science ®Google Scholar
• HernandezISmithKJZhangYCost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with AF at high risk of bleeding and normal kidney functionThromb Res201715012313027771008
   PubMed Web of Science ®Google Scholar
• SterneJABodaliaPNBrydenPAOral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in AF: systematic review, network meta-analysis and cost-effectiveness analysisHealth Technol Assess20172191386
   Web of Science ®Google Scholar
• IoannouAMetaxaSKassianosGMissourisCGAnticoagulation for the prevention of stroke in non-valvular AF in general practice: room for improvementDrugs Context2016521229527403193
   PubMedGoogle Scholar
• KirchhofPAmmentorpBDariusHManagement of AF in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events European Registry in AF (PREFER in AF)Europace201416161424084680
   PubMed Web of Science ®Google Scholar
• KasmeridisCApostolakisSEhlersLRasmussenLHBorianiGLipGYCost effectiveness of treatments for stroke prevention in AF: focus on the novel oral anticoagulantsPharmacoeconomics2013311197198024085625
   PubMed Web of Science ®Google Scholar
• HealeyJSConnollySJGoldMRASSERT InvestigatorsSub-clinical AF and the risk of strokeN Engl J Med2012366212012922236222
   PubMed Web of Science ®Google Scholar
• LopesRDAlingsMConnollySJRationale and design of the apixaban for the reduction of thrombo-embolism in patients with device-detected sub-clinical AF (ARTESiA) trialAm Heart J201718913714528625370
   PubMed Web of Science ®Google Scholar
• LipGYGittAKLe HeuzeyJYOvertreatment and undertreatment with anticoagulation in relation to cardioversion of atrial fibrillation (the RHYTHM-AF study)Am J Cardiol2014113348048424332698
   PubMed Web of Science ®Google Scholar
• KhanIAAtrial stunning: basics and clinical considerationsInt J Cardiol2003922–311312814659842
   PubMed Web of Science ®Google Scholar
• European Heart Rhythm AssociationEuropean Association for Cardio-Thoracic SurgeryCammAJKirchhofPLipGYGuidelines for the management of AF: the task force for the management of AF of the European Society of Cardiology (ESC)Eur Heart J201031192369242920802247
   PubMed Web of Science ®Google Scholar
• FlakerGLopesRDAl-KhatibSMARISTOTLE InvestigatorsEfficacy and safety of apixaban in patients after cardioversion for AF: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in AF)J Am Coll Cardiol201463111082108724211508
   PubMed Web of Science ®Google Scholar
• FunatsuTKobayashiJNakajimaHIbaYShimaharaYYagiharaTLong-term results and reliability of cryothermic ablation based maze procedure for atrial fibrillation concomitant with mitral valve surgeryEur J Cardiothorac Surg200936226727119414270
   PubMed Web of Science ®Google Scholar
• ShahRRPillaiASchaferPSafety and efficacy of uninterrupted apixaban therapy versus warfarin during AF ablationAm J Cardiol2017120340440728595862
   PubMed Web of Science ®Google Scholar
• NagaoTIndenYShimanoMEfficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillationPacing Clin Electrophysiol201538215516325487164
   PubMed Web of Science ®Google Scholar
• Di BiaseLLakkireddyDTrivediCFeasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for AF: results from a multicenter studyHeart Rhythm20151261162116825728754
   PubMed Web of Science ®Google Scholar
• PollackCVJrReillyPAEikelboomJIdarucizumab for dabigatran reversalN Engl J Med2015373651152026095746
   PubMed Web of Science ®Google Scholar
• ConnollySJMillingTJJrEikelboomJWANNEXA-4 InvestigatorsAndexanet alfa for acute major bleeding associated with factor Xa inhibitorsN Engl J Med2016375121131114127573206
   PubMed Web of Science ®Google Scholar